You may be right because this is the 2nd major negative announcement.
The first came just prior to FDA approval when the stock plummeted on negative spin.... then the approval came in and rocket.
This is indeed a strange stock with somebody making missives that are not necessarily "the whole truth and nothing but the truth".
I do not have any position in DNDN, neither long nor short. If I did, I might write to the SEC asking a bunch of questions such as "Who benefited from this filing?"
The REAL problem for DNDN may be the number on the balance sheet "retained earnings" to the tune of Retained Earnings ($2,287,538,000) negative retained earnings. It is ok for a stock like this to have up to $500 million negative retained earnings but not over 2 billion.
The other issue is the long term debt number which is what the 10-Q filing referenced. Not good.